Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2005-09-13
2005-09-13
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S563000, C514S568000, C514S569000
Reexamination Certificate
active
06943192
ABSTRACT:
Herein is disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetylglutamine and phenylacetylisoglutamine in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. In a further embodiment, herein is also disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetate and (phenylacetylglutamine or phenylacetylisoglutamine) in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. Herein are also disclosed the pharmaceutical compositions used in the above methods.
REFERENCES:
patent: 4284647 (1981-08-01), Brusilow
patent: 4470970 (1984-09-01), Burzynski
patent: 5244922 (1993-09-01), Burzynsky
patent: 5254587 (1993-10-01), Burzynski
patent: 5605930 (1997-02-01), Samid
patent: WO 93 24123 (1993-12-01), None
patent: WO 97 42939 (1997-11-01), None
Carter et al., Chemotherapy of Cancer, 2ndedition, John Wiley & Sons, NY, NY, 1981, pp356, and 362-365.
Burzynski et al., “Toxicology Studies on Antineoplaston AS2-1 Injections in Cancer Patients,”Drugs. Exptl. Clin. Res., Suppl. 1, XII:25-35 (1986).
Burzynski et al., “Preclinical Studies on Antineoplaston AS2-1 and Antineoplaston AS2-5,”Drugs. Exptl. Clin. Res., Suppl. 1, XII:11-16 (1986).
Prados et al., “Protocol NABTC 9402: Phase II Trial of Phenylacetic Acid for Recurrent Malignant Glioma,” http://cc.ucsf.edu/Pr/NATBTC_9402.pr.html, pp. 1-13 (Aug. 29, 1996).
Buckner et al., “Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC620261) in Patients with Recurrent Glioma”,Mayo Clinic Proceedings, vol. 74, No. 2, Feb. 1, 1999, pp. 137-145.
Chang et al, “Phase II Study of Pheylacetate in Patients with Recurrent Malignant Glioma: A North American Brain Tumor consortium Report”, Journal of Clinical Oncology, vol. 17, No. 3, Mar. 1999, pp. 984-990.
Thibault et al, “Phase I Study of Pheylacetate Administered Twice Daily to Patients with Cancer”, CANCER, vol. 75, 1995, pp. 2932-2938.
Thibault et al, “A Phase I Study of the Differentiating Agent Phenyl Utyrate in Patients with Cancer”, Annals of Oncology, vol. 7, No. s1, 1996, p. 63.
Piscitelli, Stephen C. et al, “Disposition of Phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine”, J. Clin. Pharmacol. (1995), 35(4), 368-73.
Burzynski and Kubove, “Toxicology Studies on Antineoplastic A10 Injections in Cancer Patients”, Drugs Exptl. Clin. Res., vol. 12 No. s1, 1986, pp. 47-55.
Burzynski, Toxicology Studies on Antineoplaston AS2-5 Injections in Cancer Patients:, Drugs Eptl. Clin. Res., vol. 12, No. s1, 1986, pp. 17-24.
Ashraf et al. “Preclinical Studies on Antineoplaston A10 Injections”; Drugs. Exptl. Clin. Res.; Suppl. 1, XII, 37-45 (1986).
Tsuda et al., “Inhibitory Effect of Antineoplaston A10 and AS2-1 on Human Hepatocellular Carcinoma”; The Kurume Medical Journal; (1996) vol. 43:137-147.
Waldbillig, Robert, J., “Pharmicokinetics of Antineoplaston A-10 and AS2-1 in patients with neoplastic disease” Report filed with FDA Mar. 14, 1997.
Waldbillig, RJ, Patil, S, and Burzynski, SR “Uptake and intracellular binding of the antineoplastic agents phenylacetic acid(PN)and phenylacetylglutamine(PG): Effects on epigenetic mechanisms of gene regulation and gene expression”, Report filed with FDA on May 26, 2004.
Burzynski, Janicki, Weaver, Jurida, Szymmkowski, Khan and Dolgopolov, “Clinical application of body epigenetic system: multi-targeted therapy for primary brain tumors” Poster at the World Conference on Dosing of Antiinfectives, Nurenberg, Germany, Sep. 9-11, 2004.
LandOfFree
Treatment regimen for administration of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment regimen for administration of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment regimen for administration of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3388372